rofecoxib

Known as: 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one, 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone, rofecoxib [Chemical/Ingredient] 
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1949-2018
010020030019492017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
BACKGROUND & AIMS In human and animal studies, nonsteroidal anti-inflammatory drugs have been associated with a reduced risk of… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. Previous… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Inflammatory mechanisms have been implicated in the pathogenesis of Alzheimer's disease (AD) and may be mediated via… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
CONTEXT Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND In comparing aspirin, nonselective nonsteroidal antiinflammatory agents (NSAIDs), and cyclooxygenase (COX)-2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective… (More)
  • figure 1
  • table 4
  • table 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
CONTEXT Nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) toxic effects, such as upper GI tract… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 12
Is this relevant?